Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

Barclays (LON:BARC) updated the rating for Bachem Holding AG (BANB:SW) stock, shifting from Underweight to Equalweight, though reducing the price target to CHF65.00 from the previous CHF71.00. The ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...